Home › Oncolytics Biotech submits Orphan Drug Designation for high grade gliomas in pediatric patients
 

Keywords :   


Oncolytics Biotech submits Orphan Drug Designation for high grade gliomas in pediatric patients

2015-02-09 15:30:43| Biotech - Topix.net

Oncolytics Biotech Inc. today announced that it has submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration for REOLYSIN for the treatment of high grade gliomas in pediatric patients. Oncolytics has conducted three previous clinical studies in brain cancers including gliomas, and has found that REOLYSIN can infect a variety of brain tumors when delivered intravenously.

Tags: high drug grade patients

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.06Eastern North Pacific Tropical Weather Outlook
29.06Atlantic Tropical Weather Outlook
29.06Tropical Storm Beryl Graphics
29.06Tropical Storm Beryl Forecast Discussion Number 2
29.06Tropical Storm Beryl Public Advisory Number 2
29.06Summary for Tropical Storm Beryl (AT2/AL022024)
29.06Tropical Storm Beryl Wind Speed Probabilities Number 2
29.06Tropical Storm Beryl Forecast Advisory Number 2
More »